Chong Kun Dang Pharmaceutical (CKD Pharm) has reported over 10 billion won of its R&D costs as assets for the first time. The cost includes increased clinical trial costs for the commercialization of its biosimilars and incrementally modified drugs (IMD). The company has gained recognition for its R&D potential following a major technology export recently, which has drawn significant attention to its drug development pipeline.

According to the Financial Supervisory Service (FSS) on 8th, the CKD’s development costs that were accounted for as intangible assets at the end of Q3 amounted to 11.6 billion won, up 2.3 billion won from 9.3 billion won reported at the end of the first half of the year, marking